In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...

A week on from increases in the cost of Eli Lilly’s weight loss drug Mounjaro (tirzepatide), weight loss medication provider ...

Novo Nordisk A/S’s slower growth will crimp employee bonuses in the Ozempic maker’s home market of Denmark as it ramps up a ...

“Semaglutide has been in the US for more than eight years now. In India also, the oral version of this molecule is there for ...

According to a report by the Financial Times, Morgan & Morgan, a law firm, revealed it had filed a case on behalf of a ...

TORONTO, Aug. 22, 2025 /CNW/ - With thousands of press releases published each week, it can be difficult to keep up with ...

A MUM thought her weight loss jabs were giving her trapped wind until she was racked by pains “worse than labour”, forcing ...

Pedersen and Maggie Fick COPENHAGEN (Reuters) -As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the ...

As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing ...

No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.